Annals of Internal Medicine,
Journal Year:
2023,
Volume and Issue:
176(10), P. ITC145 - ITC160
Published: Oct. 1, 2023
COVID-19,
the
illness
caused
by
SARS-CoV-2,
became
a
worldwide
pandemic
in
2020.
Initial
clinical
manifestations
range
from
asymptomatic
infection
to
mild
upper
respiratory
but
may
progress
pulmonary
involvement
with
hypoxemia
and,
some
cases,
multiorgan
involvement,
shock,
and
death.
Older
adults,
pregnant
persons,
those
common
comorbidities,
immunosuppression
are
at
greatest
risk
for
progression.
Vaccination
is
effective
preventing
symptomatic
reducing
severe
disease,
hospitalization,
Antiviral
treatment
immunomodulators
have
been
shown
benefit
certain
patients.
This
article
summarizes
current
recommendations
on
prevention,
diagnosis,
management,
of
COVID-19.
The Lancet Regional Health - Western Pacific,
Journal Year:
2023,
Volume and Issue:
41, P. 100917 - 100917
Published: Oct. 3, 2023
Oral
Antiviral
(OAV)
COVID-19
treatments
are
widely
used,
but
evidence
for
their
effectiveness
against
the
Omicron
variant
in
higher
risk,
vaccinated
individuals
is
limited.Retrospective
study
of
two
cohorts
cases
aged
≥70
years
diagnosed
during
a
BA.4/5
wave
Victoria,
Australia.
Cases
received
either
nirmatrelvir-ritonavir
or
molnupiravir
as
only
treatment.
Data
linkage
and
logistic
regression
modelling
was
used
to
evaluate
association
between
treatment
death
hospitalisation
compared
with
no
treatment.Of
38,933
mortality
population,
13.5%
(n
=
5250)
nirmatrelvir-ritonavir,
51.3%
19,962)
35.2%
13,721)
were
untreated.
Treatment
associated
57%
(OR
0.43,
95%
CI
0.36-0.51)
reduction
odds
death,
73%
0.27,
0.17-0.40)
55%
0.45,
0.38-0.54)
molnupiravir.
31%
0.69,
0.55-0.86)
hospitalisation,
40%
0.60,
0.43-0.83)
29%
0.71,
0.58-0.87)
treated
within
1
day
diagnosis
had
61%
0.39,
0.33-0.46)
33%
delay
4
more
days
0.67,
0.44-0.97).Treatment
both
era.
Timely,
equitable
OAVs
an
important
tool
fight
COVID-19.There
funding
this
study.
American Journal of Therapeutics,
Journal Year:
2024,
Volume and Issue:
31(3), P. e246 - e257
Published: April 29, 2024
Background:
Nirmatrelvir/ritonavir
(NMV/r)
is
an
oral
antiviral
drug
used
to
treat
mild-to-moderate
coronavirus
disease
2019
(COVID-19)
in
patients
aged
12
years
or
older
at
high
risk
of
progression
severe
(eg,
hospitalization
and
death).
Despite
being
the
preferred
option
for
outpatient
treatment
majority
countries
worldwide,
NMV/r
currently
underutilized
real-world
clinical
practice.
Areas
Uncertainty:
As
numerous
studies
have
described
patient
outcomes
following
with
NMV/r,
this
systematic
literature
review
provides
a
comprehensive
summary
evidence
on
effectiveness
against
mortality
further
organized
by
clinically
meaningful
categories,
such
as
acute
versus
longer-term
follow-up,
age,
underlying
health
conditions,
vaccination
status,
help
inform
care
decision
making.
Data
Sources:
We
searched
Embase
PubMed
(December
22,
2021–March
31,
2023)
congress
abstracts
1,
2021–December
2022)
reports
describing
effectiveness.
Therapeutic
Advances:
In
total,
18
met
final
selection
criteria.
The
showed
that
significantly
reduced
postinfection
all-cause
COVID-19-related
both
(≤30
days)
(21%–92%)
(>30
(1%–61%)
follow-up.
reduction
was
higher
when
received
within
5
days
symptom
onset.
Real-world
observed
regardless
high-risk
status.
Conclusion:
findings
demonstrated
during
Omicron
period
among
individuals
COVID-19
disease.
Annals of Internal Medicine,
Journal Year:
2023,
Volume and Issue:
176(10), P. ITC145 - ITC160
Published: Oct. 1, 2023
COVID-19,
the
illness
caused
by
SARS-CoV-2,
became
a
worldwide
pandemic
in
2020.
Initial
clinical
manifestations
range
from
asymptomatic
infection
to
mild
upper
respiratory
but
may
progress
pulmonary
involvement
with
hypoxemia
and,
some
cases,
multiorgan
involvement,
shock,
and
death.
Older
adults,
pregnant
persons,
those
common
comorbidities,
immunosuppression
are
at
greatest
risk
for
progression.
Vaccination
is
effective
preventing
symptomatic
reducing
severe
disease,
hospitalization,
Antiviral
treatment
immunomodulators
have
been
shown
benefit
certain
patients.
This
article
summarizes
current
recommendations
on
prevention,
diagnosis,
management,
of
COVID-19.
